Dramatic Reduction in Tumor Burden With Neoadjuvant Sunitinib Prior to Bilateral Nephron-sparing Surgery - 06/02/12
Doi : 10.1016/j.urology.2011.04.018
Michael A. Gorin a, Obi Ekwenna a, Mark S. Soloway a, Gaetano Ciancio a, b, ⁎ 
a Department of Urology, Division of Transplantation, University of Miami, Miller School of Medicine, Miami, FL
b Department of Surgery, Division of Transplantation, University of Miami, Miller School of Medicine, Miami, FL
Reprint requests: Gaetano Ciancio, M.D., Department of Surgery, Division of Transplantation, University of Miami, Miller School of Medicine, PO Box 012440, Miami, FL 33101Résumé |
Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.
Le texte complet de cet article est disponible en PDF.© 2012
Elsevier Inc. Tous droits réservés.
Vol 79 - N° 2
P. e11 - février 2012 Retour au numéro
Article précédent
- Clinical Stage T1 Micropapillary Urothelial Carcinoma Presenting With Metastasis to the Pancreas
- Daniel Canter, Jay Simhan, Marc C. Smaldone, Brett Lebed, Jeffrey L. Tokar, Karen N. Wu, Robert G. Uzzo, Karen S. Gustafson, Arthur S. Patchefsky, Elizabeth R. Plimack, John P. Hoffman, Alexander Kutikov
- Colocalycostomy for Repair of Ureterojejunal Fistula
- Liyan Zhuang, Brian D. Duty, Michael J. Conlin, Siamak Daneshmand
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?